News

PMLive8h
FDA approves Abeona’s epidermolysis bullosa gene therapy Zevaskyn
The US Food and Drug Administration (FDA) has approved Abeona Therapeutics’ Zevaskyn (prademagene zamikeracel) for use in ...
Daily Jang6h
Zevaskyn receives FDA approval for rare, genetic skin disorder
The U.S. Food and Drug Administration has approved Zevaskyn for patients suffering from rare, genetic skin disease recessive ...
GlobalData on MSN1d
FDA approves Abeona’s $3.1m cell therapy for rare skin disease
Abeona has won FDA approval for Zevaskyn, setting up a commercial challenge to Krystal Biotech in the rare skin disease ...
Medscape2d
FDA Approves First One-Time Topical Treatment for Recessive Dystrophic Epidermolysis Bullosa Wounds
In a phase 3 trial, 81% of wounds treated with autologous cell sheet-based gene therapy showed ≥ 50% healing at 6 months, ...
BioPharma Dive2d
Abeona cell therapy approved by FDA for rare skin condition
Zevaskyn, which Abeona priced at $3.1 million, treats epidermolysis bullosa. It will compete with a gene therapy from Krystal ...
Zacks Small Cap Research on MSN1d
ABEO: Zevaskyn™ Approved by FDA; Raising Valuation to $11…
(NASDAQ:ABEO) announced that the U.S. Food and Drug Administration (FDA) has approved Zevaskyn (prademagene zamikeracel) for the treatment of wounds in adults and children with recessive dystrophic ...
US FDA approves first cell-based gene therapy for rare genetic skin disorder
The U.S. Food and Drug Administration approved Abeona Therapeutics' gene therapy for a rare skin disorder on Tuesday. The ...
Healio2d
FDA approves Zevaskyn for treatment of recessive dystrophic epidermolysis bullosa
The FDA has approved Zevaskyn for the treatment of recessive dystrophic epidermolysis bullosa, the company announced in a ...
Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease
Abeona's Zevaskyn secures timely FDA nod, priced at $3.1 million, with 2025 sales now forecast at $31.6 million and peak U.S. revenue projected at $600 million.
Abeona Therapeutics Wins FDA Approval For First-of-Its-Kind Gene Therapy
The U.S. Food and Drug Administration (FDA) on Tuesday approved Abeona Therapeutics Inc.’s (NASDAQ:ABEO) Zevaskyn ...
Abeona Stock Surges to 52-Week High: What's Behind The Move?
Abeona shares are trading higher on Wednesday on possible continued strength after the FDA announced approval for its gene ...
FDA approves Zevaskyn for rare, genetic skin disorder
The U.S. Food and Drug Administration has approved Abeona Therapeutics' Zevaskyn (prademagene zamikeracel) for patients with ...